Core 1: Analytical and Pharmacokinetics Core PI: William Zamboni, Pharm. D., Ph.D. William Zamboni is an Associate Professor in the Eshelman School of Pharmacy. He is the Director of GLP Analytical Facility, Center for Experimental Therapeufics and the Director of the Translational Oncology and Nanoparticle Drug Development Inifiafive (T0ND2I) Lab at UNC. He has been involved in translational studies of anticancer agents for several years. His research interests focus on the application of pharmacokinetic, pharmacodynamic, and pharmacogenetic principles in the optimizafion of the chemotherapeufic treatment of cancer. He is also developing nanosomal and nanoparticle anticancer agents and evaluating the relafionship between the disposition of these agents and the reticuloendothelial system. As part of these studies, he has used microdialysis to evaluate the tumor extracellular fluid disposition of anticancer agents and factors affecting the delivery and removal of anticancer agents. He has also developed methods and technologies to differentiate between the inactive-encapsulate and active-release forms of the drugs and are evaluafing potential phenotypic probes from the pharmacokinetic and pharmacodynamic disposition of nanosomal and nanoparticles. The clinical relevance of studies is underscored by the need to treat solid tumors with anticancer agents that have a high tumor delivery of liposomal and nanoparticle agents, and generate administration schedules to enhance selective tumor uptake.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
1U54CA151652-01
Application #
7982957
Study Section
Special Emphasis Panel (ZCA1-GRB-S (M1))
Project Start
2010-09-01
Project End
2015-07-31
Budget Start
2010-09-01
Budget End
2011-07-31
Support Year
1
Fiscal Year
2010
Total Cost
$80,758
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Sun, Junjiang; Shao, Wenwei; Chen, Xiaojing et al. (2018) An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs. Mol Ther Methods Clin Dev 10:257-267
Liu, Lina; Wang, Yuhua; Miao, Lei et al. (2018) Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer. Mol Ther 26:45-55
Starling, Brittney R; Kumar, Parag; Lucas, Andrew T et al. (2018) Mononuclear phagocyte system function and nanoparticle pharmacology in obese and normal weight ovarian and endometrial cancer patients. Cancer Chemother Pharmacol :
Chai, Zheng; Zhang, Xintao; Rigsbee, Kelly Michelle et al. (2018) Cryoprecipitate augments the global transduction of the adeno-associated virus serotype 9 after a systemic administration. J Control Release 286:415-424
Wang, Yuhua; Zhang, Lu; Xu, Zhenghong et al. (2018) mRNA Vaccine with Antigen-Specific Checkpoint Blockade Induces an Enhanced Immune Response against Established Melanoma. Mol Ther 26:420-434
Pei, Xiaolei; He, Ting; Hall, Nikita E et al. (2018) AAV8 virions hijack serum proteins to increase hepatocyte binding for transduction enhancement. Virology 518:95-102
Zhang, Xintao; He, Ting; Chai, Zheng et al. (2018) Blood-brain barrier shuttle peptides enhance AAV transduction in the brain after systemic administration. Biomaterials 176:71-83
Satterlee, Andrew B; Attayek, Peter; Midkiff, Bentley et al. (2017) A dosimetric model for the heterogeneous delivery of radioactive nanoparticles In vivo: a feasibility study. Radiat Oncol 12:54
Miao, Lei; Liu, Qi; Lin, C Michael et al. (2017) Targeting Tumor-Associated Fibroblasts for Therapeutic Delivery in Desmoplastic Tumors. Cancer Res 77:719-731
Goodwin, Tyler J; Shen, Limei; Hu, Mengying et al. (2017) Liver specific gene immunotherapies resolve immune suppressive ectopic lymphoid structures of liver metastases and prolong survival. Biomaterials 141:260-271

Showing the most recent 10 out of 190 publications